WuXi Cellular Therapy Appoints Tian Feng as Chairman and CEO Amid Governance Restructuring

Click the image to view conference details↑↑↑

On June 26, JW Therapeutics’ (02126.HK) Annual General Meeting of Shareholders concluded, with multiple routine agenda items duly approved; however, an unexpected development arose during the re-election of directors:Proposals for the Re-election of Two Non-Executive Directors Were Voted Down by Shareholders in Succession。

Routine agenda items, including the review of the annual audited financial statements, the reappointment of auditors, and the general mandates for share issuance and repurchase, were all duly passed with overwhelming support. However, the resolutions for the re-election of Dr. Liu Cheng and Dr. Sungwon Song as non-executive directors failed to pass, as they did not meet the majority threshold; the final vote in favor accounted for only 45.21%, while votes against reached 54.79%.This was not a routine departure upon the expiration of a standard term, but rather a definitive block by shareholders that barred him from the boardroom.

Source:JW Therapeutics Announcement

Tian Feng Takes the Baton

With the failure of the re-election proposal, Dr. Liu Cheng officially stepped down from his position as Non-Executive Director and concurrently ceased to perform the duties associated with the role of Chairman of the Board of Directors of JW Therapeutics. Dr. Sungwon Song also withdrew from the Company’s Board of Directors at the same time.

On the day of the meeting, the company immediately announced a new personnel adjustment plan: Tian Feng, Executive Director and Chief Executive Officer, was appointed as Chairman of the Board, effective June 26.

Since then, Tian Feng has concurrently held the two core management positions of Chairman of the Board and CEO, marking JW Therapeutics’ formal entry into a governance phase with combined leadership.

2、Deviating from HKEX Code: A Pursuit of Efficiency

In accordance with the Corporate Governance Code of the Hong Kong Stock Exchange, the roles of Chairman of the Board and Chief Executive Officer should, in principle, be held by separate individuals to avoid excessive concentration of power. JW Therapeutics also acknowledged in its announcement that the current arrangement deviates from the relevant code requirements.

However, the board of directors provided a straightforward rationale: having the same individual serve in both roles helps the company establish unified leadership and enables more efficient formulation and execution of business strategies.

Behind this statement lies the tangible survival pressure in the cell therapy sector. With lengthy R&D cycles, significant hurdles to commercialization, sustained cash flow strain, and intensifying industry competition, every decision must be made without delay. If management authority and responsibilities are fragmented and consensus-building is slow, companies risk missing critical development windows amid industry cycles.

3. Board downsizing, more centralized power, ultimately speaking through business performance

Following the implementation of this round of personnel adjustments, the board of directors of JW Therapeutics has been reduced to six members: Tian Feng, Executive Director and Chairman; Li Yiping and Gao Xing, Non-Executive Directors; and three Independent Non-Executive Directors. The composition of its supporting committees has also been updated concurrently, with Gao Xing officially appointed as a member of the Remuneration Committee.

On the surface, it appears to be routine personnel changes; in essence, it represents a consolidation of authority and responsibility at the corporate governance level. The board structure has been streamlined, further centralizing the core decision-making power, and Tian Feng has been propelled to the most central position in the company’s management.

For the capital markets, personnel changes are merely procedural details. The true core focus lies in whether JW Therapeutics, with the dawn of the “Tian Feng Era,” can deliver a clearer strategic roadmap, more efficient execution pace, and more solid commercialization results. Adjustments to the governance structure are ultimately just a means; tangible business performance remains the ultimate benchmark for evaluation.

Source:Official AccountDi Yi Consulting

*This WeChat official account maintains a neutral stance toward all original and reposted content, statements, and viewpoints. The materials shared are intended solely for non-commercial, public-interest purposes. If any reposted works or images contain incorrect authorship attributions or involve copyright infringement, please kindly notify the original authors and contact the editor for removal.

*Executive Editor| Muyi

*Reprint Permission |Xiao E 13166175613 (WeChat ID same as phone number))

*Business Cooperation | LiuTeacher13262726197(WeChat ID same as phone number)